Advertisement
LIFE vs SER
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIFE is a Hold and SER is a Hold.
LIFE in downward trend: price may drop because broke its higher Bollinger Band on October 21, 2026
LIFE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 27 similar instances where the stock broke above the upper band. In 23 of the 27 cases the stock fell afterwards. This puts the odds of success at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for LIFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 19 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on LIFE as a result. In 41 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for LIFE just turned positive on October 12, 2026. Looking at past instances where LIFE's MACD turned positive, the stock continued to rise in 19 of 22 cases over the following month. The odds of a continued upward trend are 86%.
LIFE moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LIFE crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIFE advanced for three days, in 132 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 84 of 98 cases where LIFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LIFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.707) is normal, around the industry mean (2.657). LIFE has a moderately low P/E Ratio (-25.534) as compared to the industry average of (18.633). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.186) is also within normal values, averaging (2.968).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
SER's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for SER moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 72 cases where SER's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on SER as a result. In 109 of 122 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for SER just turned positive on October 27, 2026. Looking at past instances where SER's MACD turned positive, the stock continued to rise in 50 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Following a +18.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SER advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SER broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SER entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. SER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.509) is normal, around the industry mean (3.104). P/E Ratio (-0.989) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LIFE | SER | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 93 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 13 | 96 | |
SMR RATING 1..100 | 96 | 100 | |
PRICE GROWTH RATING 1..100 | 34 | 61 | |
P/E GROWTH RATING 1..100 | 99 | 31 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LIFE's Valuation (65) in the Biotechnology industry is in the same range as SER (70) in the null industry. This means that LIFE’s stock grew similarly to SER’s over the last 12 months.
LIFE's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for SER (96) in the null industry. This means that LIFE’s stock grew significantly faster than SER’s over the last 12 months.
LIFE's SMR Rating (96) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that LIFE’s stock grew similarly to SER’s over the last 12 months.
LIFE's Price Growth Rating (34) in the Biotechnology industry is in the same range as SER (61) in the null industry. This means that LIFE’s stock grew similarly to SER’s over the last 12 months.
SER's P/E Growth Rating (31) in the null industry is significantly better than the same rating for LIFE (99) in the Biotechnology industry. This means that SER’s stock grew significantly faster than LIFE’s over the last 12 months.
| LIFE | SER | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Advances ODDS (%) | 5 days ago 78% | 4 days ago 83% |
| Declines ODDS (%) | 1 day ago 85% | 6 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIFE’s FA Score shows that 1 FA rating(s) are green while SER’s FA Score has 1 green FA rating(s).
- LIFE’s FA Score: 1 green, 4 red.
- SER’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIFE’s TA Score shows that 6 TA indicator(s) are bullish while SER’s TA Score has 5 bullish TA indicator(s).
- LIFE’s TA Score: 6 bullish, 4 bearish.
- SER’s TA Score: 5 bullish, 3 bearish.
Price Growth
LIFE (@Insurance Brokers/Services) experienced а +0.76% price change this week, while SER (@Biotechnology) price change was +8.19% for the same time period.
The average weekly price growth across all stocks in the @Insurance Brokers/Services industry was +0.82%. For the same industry, the average monthly price growth was +10.48%, and the average quarterly price growth was +16.64%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.92%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -20.21%.
Reported Earning Dates
SER is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Insurance Brokers/Services (+0.82% weekly)Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.
@Biotechnology (-0.92% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LIFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, LIFE has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LIFE jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To LIFE | 1D Price Change % | ||
|---|---|---|---|---|
| LIFE | 100% | -1.77% | ||
| MDGL - LIFE | 34% Loosely correlated | +0.18% | ||
| SER - LIFE | 34% Loosely correlated | -4.64% | ||
| TNYA - LIFE | 33% Poorly correlated | -1.74% | ||
| NTLA - LIFE | 32% Poorly correlated | -6.50% | ||
| AXON - LIFE | 32% Poorly correlated | -0.55% | ||
More | ||||
SER and
Correlation & Price change
A.I.dvisor indicates that over the last year, SER has been loosely correlated with GERN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SER jumps, then GERN could also see price increases.
| Ticker / NAME | Correlation To SER | 1D Price Change % | ||
|---|---|---|---|---|
| SER | 100% | -4.64% | ||
| GERN - SER | 65% Loosely correlated | +3.88% | ||
| XTLB - SER | 59% Loosely correlated | +13.04% | ||
| ELVN - SER | 37% Loosely correlated | +0.86% | ||
| TOVX - SER | 34% Loosely correlated | +7.92% | ||
| LIFE - SER | 34% Loosely correlated | -1.77% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OMFS | 50.05 | 0.27 | +0.55% |
| Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) | |||
| EVSM | 49.85 | 0.01 | +0.01% |
| Eaton Vance Short Duration Municipal Income ETF (EVSM) | |||
| GJT | 23.01 | N/A | N/A |
| Synthetic Fixed-Income Securities STRATS 2006-3 AllState Corp | |||
| WLTG | 37.60 | -0.11 | -0.30% |
| WealthTrust DBS Long Term Growth ETF (WLTG) | |||
| VRAI | 28.63 | -0.30 | -1.03% |
| Virtus Real Asset Income ETF (VRAI) | |||